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CTLA-­4  is  a  critical  gatekeeper  of  T-­cell  activation  and  immunological  tolerance  and  
has  been  implicated  in  patients  with  a  variety  of  autoimmune  diseases  through  genetic  
association.  Since  T  cells  from  patients  with  the  autoimmune  disease  systemic  lupus  
erythematosus  (SLE)  display  a  characteristic  hyperactive  phenotype,  we  investigated  
the   function  of  CTLA-­4   in  SLE.  Our   results   reveal   increased  CTLA-­4  expression   in  
FOXP3  responder  T  cells  from  patients  with  SLE  compared  with  other  autoimmune  
rheumatic  diseases  and  healthy  controls.  However,  CTLA-­4  was  unable  to  regulate  T-­
cell  proliferation,  lipid  microdomain  formation  and  phosphorylation  of  TCR-­f  following  
CD3/CD28   costimulation,   in   contrast   to   healthy   T   cells.   Although   lupus   T   cells  
responded   in   vitro   to   CD3/CD28   co-­stimulation,   there   was   no   parallel   increase   in  
CTLA-­4   expression,   which   would   normally   provide   a   break   on   T-­cell   proliferation.  
These   defects  were   associated  with   exclusion   of   CTLA-­4   from   lipid  microdomains  
providing   an   anatomical   basis   for   its   loss   of   function.  Collectively   our   data   identify  
CTLA-­4  dysfunction  as  a  potential  cause  for  abnormal  T-­cell  activation  in  patients  with  








CTB:   cholera   toxin   subunit   B   GM1:   glycosphingolipid,   PsA:   psoriatic   arthritis   RA:  
rheumatoid  arthritis  SLE:  systemic  lupus  erythematosus  
Introduction  
The  immune  response  to  antigen  is  controlled  by  potent  negative  regulators  of  TCR  
signalling,  including  the  CD28  homologue,  CTLA-­4.  The  importance  of  CTLA-­4  in  the  
down-­modulation  of  immune  responses  is  demonstrated  in  CTLA-­4-­deficient  mice  that  
develop  a  lethal  lymphoproliferative  syndrome  with  features  of  autoimmunity  [1,  2].  It  
is  worth  noting  that  by  3–5  wk,  CTLA-­4-­deficient  mice  suffer  from  a  severe  lupus-­like  
autoimmune   syndrome,  which   is  more   rapid   in   onset   than   other  mouse  models   of  
systemic  lupus  erythematosus  (SLE)  [3].    
Several  mechanisms  have  been  proposed  to  explain  the  molecular  basis  for  CTLA-­4  
inhibition  including  a  dampening  of  T-­cell  signalling  responses  and  alterations  in  T-­cell  
motility   [4,   5].   The   location   and   interaction   of   CTLA-­4   within   membrane   lipid  
microdomains  also  influences  its  inhibitory  function.  In  healthy  activated  T  cells,  co-­
ligation   of   CTLA-­4   during   TCR   stimulation   strongly   inhibits   the   upregulation   of  
membrane   lipid   microdomains   enriched   with   proximal   signalling   molecules   [6,   7].  
Moreover,  although  the  surface  expression  of  CTLA-­4  is  tightly  regulated,  during  T-­
cell  activation  a  pool  of  cell  surface  CTLA-­4  is  concentrated  in  lipid  microdomains  and  
associates   with   the   TCR-­z   chain   [7,   8].   This   suggests   that   CTLA-­4   controls   TCR  
accumulation/retention   in  membrane  microdomains   thereby  blocking   formation  of  a  
stable  immunological  synapse  and  downstream  signalling  events.  In  addition,  CTLA-­
4  is  constitutively  expressed  on  the  majority  of  Treg,  and  plays  an  important  role  in  
their  function  [9–12].  The  relative  contribution  of  CTLA-­4  to  the  intrinsic  regulation  of  
responder  T-­cell  activation  and  Treg  function  remain  unclear.  
We  and  others  have  shown  that  lupus  T  cells  display  signaling  patterns  characteristic  
of  hyper-­responsiveness  and  altered  expression  of  molecules  regulated  by  CTLA-­4,  
such   as   unregulated   TCRz   phosphorylation   and   increased   expression   of   lipid  
microdomain-­associated  glycosphingolipid  (GM1)  [13–16].  Furthermore  lupus  T  cells  
demonstrate  more  rapid  formation  of  a  stable  immunological  synapse  [17,  18],  which  
is   normally   inhibited  by  CTLA-­4   [19].  We   reasoned,   therefore,   that  CTLA-­4  maybe  
defective  in  its  ability  to  inhibit  activation  in  lupus  T  cells.  Genetic  studies  linking  CTLA-­
4  with  SLE  provide  an  additional   rationale   to   investigate   the   role  of  CTLA-­4   in   the  
pathogenesis  of  this  disease.  Indeed,  an  association  between  CTLA-­4  polymorphisms  
and  lupus  has  been  found  in  numerous  studies  around  the  world  [20–27].  In  addition,  
increased  CTLA-­4  expression  has  been  noted  in  T  cells  from  patients  with  SLE  [28].  
Here  we  demonstrate  that  despite  the  significantly  increased  expression  of  CTLA-­4  in  
T  responder  cells  from  patients  with  SLE  compared  with  healthy  controls,  its  ability  to  
regulate   lupus  T-­cell   signalling  and  proliferation   following  CD3/CD28  co-­stimulation  
was   impaired.   This   defect   was   associated   with   exclusion   of   CTLA-­4   from   lipid  
microdomains,  which  could  account  for  its  loss  of  function  in  T  cells  from  patients  with  
SLE.   These   data,   identifying   dysfunctional  CTLA-­4   in   responder   T   cells   indicate   a  
disturbance   in   the   immunoregulatory   pathway   of   lupus   patients,   and   provide   a  




CTLA-­4  expression  is  significantly  increased  in  T  cells  from  patients  with  SLE  
Patients  with   SLE   show   increased   levels   of  membrane  GM1   and   cholesterol   [14],  
molecules   that   are   downregulated   by   the   inhibitory   co-­receptor   CTLA-­4   [6]].   This  
encouraged  us  to  investigate  CTLA-­4  expression  in  ex  vivo  PBMC  from  lupus  patients  
compared  with  healthy  controls  by  flow  cytometry.  In  agreement  with  a  previous  report  
[28],  a  significant  increase  in  the  expression  of  total  (t)  CTLA-­4  was  seen  in  CD4+  T  
cells  from  patients  over  healthy  controls  (Fig.  1A;;  %,  p=0.0002;;  MFI,  p=0.01).  Although  
the   change   in   the   percentage   of   lupus   T   cells   expressing  CTLA-­4  was   small,   this  
represented  a  twofold  increase  compared  with  T  cells  from  healthy  individuals.  The  
more   substantial   shift   in   CTLA-­4   expression   as   measured   by   MFI   suggests   that  
increased   CTLA-­4   expression   affects   a   high   proportion   of   lupus   T   cells.   Surface  
(s)CTLA-­4  expression  was  low  in  ex  vivo  T  cells  from  healthy  donors  but  significantly  
increased   in   lupus  patients   (p=0.01)   (Fig.  1B).  The  elevation   in  CTLA-­4  expression  
was  independent  of  lupus  disease  activity  status.  No  increase  in  tCTLA-­4  expression  
was  noted  in  T  cells  isolated  from  patients  with  other  autoimmune  rheumatic  diseases,  
(rheumatoid  arthritis,  RA  and  psoriatic  arthritis,  PsA)  (Fig.  1C).  
  
  
Increased   CTLA-­4   in   lupus   is   independent   of   FOXP3   but   associated   with  
increased  T  cell  activation  
Since   CTLA-­4   is   an   important   marker   of   Treg,   [9],   we   investigated   whether   its  
increased  expression  in  lupus  patients  was  associated  with  this  population.  However,  
the   expression   of   CTLA-­4   was   increased   significantly   in   the   FOXP3–   negative  
population  from  lupus  patients  compared  with  healthy  controls  
(p=   0.008)   (Fig.   2A)   indicating   that   the   lupus-­associated   upregulation   of   CTLA-­4  
resides  within   the   responder  T-­cell  population.   In  contrast,   there  was  no  change   in  
CTLA-­4   expression   in   the   FOXP3+   population   from   lupus   patients   compared   with  
healthy  controls  (Fig.  2A).  
Increased  levels  of  CTLA-­4  are  also  characteristic  of  activated  and  memory  T  cells  
associated   with   downmodulation   of   CD28   [4,   29,   30].   Almost   all   CTLA-­4+   T   cells  
expressed  CD28,  but  the  level  of  CD28  expression  in  the  CTLA-­4+  population  in  lupus  
T  cells  was  significantly  reduced  compared  with  healthy  controls  (p=0.0001)  (Fig.  2B),  
consistent   with   their   hyperactive   phenotype.   There   was   a   significant   population   of  
CD28-­   T   cells,   which   did   not   express   CTLA-­4,   in   lupus   patients,   which   has   been  
previously  described  [31,  32].  We  found  increased  proliferation  in  lupus  responder  T  
cells  using  the  proliferation  marker  Ki67.  
The  FOXP3-­  responder  T  cells  showed  a  significant  increase  in  Ki67  staining  in  lupus  
patients   compared   with   controls   (p=0.006)   (Fig.   2C),   indicating   marked   T-­cell  
proliferation  in  lupus  T  cells.  There  was  a  substantial  increase  in  CD4+FOXP3+  
T   cells   in   lupus   patients   (Fig.   2D),  which   has   been   suggested   by   others   to   reflect  
increased  T-­cell   activation   [33].   tCTLA-­4  expression  was   increased   in   the  FOXP3-­
Ki67+  population  in  lupus  T  cells  compared  with  healthy  controls  (p=0.01)  (Fig.  2E)  
indicating  that  CTLA-­4  is  upregulated  on  activated  T  cells  in  lupus  patients.  There  was  
no  difference  in  CLTA-­4  expression  in  the  CD4+FOXP3+Ki67+  population  (Jury  and  
Ehrenstein,  unpublished  data).  Together,  these  results  indicate  that  the  elevated  
CTLA-­4  expression  is  attributable  to  increased  T-­cell  activation  in  the  lupus  patients  
and  is  associated  with  increased  numbers  of  FOXP3+  T  cells.  
  
  
In  vitro  activation  does  not  induce  further  CTLA-­4  upregulation  in  lupus  T  cells  
To   examine   the   effect   of   activation   on   CTLA-­4   expression,   CD4+CD25-­CD127+  
responder  T  cells  from  lupus  patients  and  controls  were  activated  in  vitro  using  anti-­
CD3  and  anti-­CD28.  CTLA-­4  expression  was  maximally  increased  after  24  h  in  the  T  
cells  from  healthy  controls  (p50.01)  (Fig.  3A).  However,  CTLA-­4  expression  was  not  
increased   in   T   cells   from   lupus   patients   as   a   consequence   of   anti-­CD3/CD28  
stimulation.  When  CTLA-­4   expression   is   increased   in   activated   T   cells   its   surface  
expression   is   tightly   regulated   by   a   process   of   recycling   to   the   plasma  membrane  
surface  [34],  with  the  majority  of  CTLA-­4  maintained  in  intracellular  stores.  To  assess  
the  recycling  dynamics  of  CTLA-­4,  purified  responder  T  cells  were  treated  with  PMA  
to  induce  its  surface  expression  [34].  Confocal  microscopy  analysis  revealed  that  ex  
vivo  PMA-­treated  T  cells  from  both  healthy  and  lupus  T  cells  show  a  similar  pattern  for  
CTLA-­4  staining  with  large  aggregates  at  or  near  the  cell  surface  (Fig.  3B,  left-­hand  
panels).  Upon  2  min  incubation,  however,  a  rapid  change  in  staining  pattern  was  seen.  
While  T  cells  from  healthy  controls  still  presented  areas  of  CTLA-­4  aggregation,  SLE  
responder  T  cells  showed  a  more  diffuse  staining  pattern,  suggesting  an   increased  
internalisation  rate  (Fig.  3B,  right-­hand  panels).  This  observation  was  supported  by  
flow   cytometry   analysis   (Fig.   3C)   where   the   percentage   internalisation   rate   was  
increased  in  ex  vivo  T  cells  from  patients  with  SLE  compared  with  healthy  controls.  In  
anti-­CD3/CD28  activated  cells  the  internalization  and  recycling  rate  of  CTLA-­4  in  the  
healthy  controls  was  increased  to  levels  observed  in  the  lupus  T  cells  but  no  increase  
in  CTLA-­4   internalisation  was  noted   in   lupus  T  cells.These  results  suggest   that   the  
regulation  of  CTLA-­4  at  the  cell  surface  is  disrupted  in  patients  with  SLE.  
  
  
Defective  inhibition  of  T-­cell  activation  by  CTLA-­4  in  SLE  
We  next  examined   the   function  of  CTLA-­4   in   the  CD4+CD25-­CD127+  responder  T  
cells  from  patients  with  SLE.  Initially,  we  noted  that  the  proliferation  of  lupus  responder  
T  cells  following  CD3/CD28  activation  was  similar  to  their  healthy  counterparts  (Fig.  
4A).  Cross-­linking  CTLA-­4  significantly   inhibited  CD3/CD28   induced  proliferation   in  
healthy   T-­cells   as   expected.   However,   no   reduction   in   anti-­CD3/CD28   driven  
proliferation  by  CTLA-­4  was  observed  in  T  cells  from  patients  with  SLE  (p=0.005)  (Fig.  
4A  and  B).  This  lack  of  control  by  CTLA-­4  on  T-­cell  proliferation  was  accompanied  by  
a   failure   to   regulate   anti-­CD3/CD28   proximal   signalling.   Cross-­linking   CTLA-­4  
significantly  reduced  the  CD3/CD28-­induced  phosphorylation  of  CD3-­z  (Fig.  4C  and  
D)  in  responder  T  cells  from  healthy  controls  but  not  in  lupus  T  cells.  Taken  together,  
the   results   suggest   that  CTLA-­4-­mediated   inhibition  of  CD3/CD28  co-­stimulation   is  
lost  in  responder  T  cells  from  patients  with  SLE.  
  
  
CTLA-­4  is  excluded  from  and  fails  to  regulate  membrane  microdomains  in  lupus  
T  cells  
To   investigate   the   established   role   of   CTLA-­4   as   an   inhibitor   of   membrane   lipid  
microdomain  formation  during  CD3/CD28  costimulation  [6],  FACS  sorted  responder  T  
cells   (CD4+CD25-­CD127+)   were   stimulated   in   vitro   using   beads   coated   with   anti-­
CD3/anti-­CD287agonistic  anti-­CTLA-­4  antibodies.  After  72  h,  a  significant  increase  in  
membrane  lipid  GM1  (measured  by  binding  to  cholera  toxin  subunit  B  (CTB)  [35]  
was  noted   in  healthy  T-­responder  cells   stimulated  via  CD3/CD28   (p=0.005),  which      
was  downregulated  by  cross-­linking  CTLA-­4  (p=0.004)  as  reported  previously  [6]  (Fig.  
5A  upper  panels).  In  contrast,  ex  vivo  responder  T  cells  from  patients  with  SLE  had  a  
higher   percentage   of   CTB1   cells,   which   increased   upon  CD3/CD28   co-­stimulation  
(p=0.04).  However,  CTLA-­4   cross-­linking   did   not   downregulate  CTB  binding   in   the  
lupus  T  cells   (Fig.  5A  bottom  panels)  supporting  a  disassociation  between  CTLA-­4  
and  lipid-­microdomain  signalling  in  lupus  T  cells.  T  cells  from  patients  with  SLE  are  
characterised  by  alterations  in  the  localisation  of  membrane  signalling  molecule  that  
can  influence  their  function  [14,  18,  36].  Therefore,  we  examined  the  location  of  CTLA-­
4   in   relation   to   lipid  microdomains   by   confocal  microscopy.  We   reasoned   that   the  
exclusion  of  CTLA-­4   from  membrane   lipid  microdomains  could  explain   its   failure   to  
regulate  CD3/CD28  co-­stimulation.  In  activated  healthy  T-­cells  the  majority  of  CTLA-­
4  was  associated  with  lipid  microdomains  (Fig.  5B,  purple  colour  in  merged  panel  and  
Fig.  5C).  In  contrast,  very  little  CTLA-­4  (blue)  and  lipid  raft  (red)  co-­localisation  was  
apparent   in   lupus  T  cells,   indicating  that  the  majority  of  CTLA-­4  was  excluded  from  
membrane   microdomains   (p=0.0006)   (Fig.   5B   and   C).   These   results   demonstrate  




The  molecular  mechanisms  that  underlie  the  aberrant  T-­cell  activation   in  SLE  have  
not  been  completely  elucidated.  Here  we  demonstrate  abnormal  CTLA-­4  expression  
and  function  in  lupus  responder  T  cells,  which  could  provide  an  explanation  
for  their  dysfunction  in  SLE.  CTLA-­4  was  unable  to  inhibit  lupus  T-­cell  proliferation  or  
regulate  the  induction  of  intracellular  pathways  induced  by  T-­cell  activation.  CTLA-­4  
was   displaced   from   membrane   microdomains   and   unable   to   regulate   either   their  
expression  or  the  intracellular  signalling  molecules  triggered  by  T-­cell  activation.  Given  
that  T  cells  genetically  engineered  to  lack  CTLA-­4  are  resistant  to  tolerance  induction  
[37],   it   is  tempting  to  speculate  that  autoreactive  lupus  T  cells  are  similarly  affected  
due   to   deficiencies   in   CTLA-­4   function.   Thus   the   exaggerated   T-­cell   responses  
characteristic  of  SLE  could  be  attributed  to  CTLA-­4  dysfunction.  Although  CTLA-­4  can  
induce  T-­cell  apoptosis  [38]  which  might  therefore  be  impaired  in  lupus  due  to  CTLA-­
4  dysfunction,  in  fact  lupus  T  cells  display  an  increased  rate  of  apoptosis  compared  
with   healthy   T-­cells   [39–42].   It   remains   to   be   determined   whether   mechanisms    
independent   of   CLTA-­4   attempt   to   delete   autoreactive   T   cells   through   increased  
apoptosis  or  their  survival  is  impaired  due  to  prolonged  stimulation.  
Lupus  T  cells  exhibited  a  marked  increase  in  proliferation  as  assessed  by  Ki67  staining  
supporting  the  notion  that  these  cells  have  received  substantial  activation  signals  in  
vivo.  CTLA-­4  expression  was  elevated  in  the  Ki671  responder  T-­cell  population  in  both  
healthy   controls   and   lupus   patients,   but   the   latter   showed   the   highest   expression  
consistent  with  their  activated  phenotype.  This  change  in  CLTA-­4  expression  in  lupus  
responder  T  cells  is  likely  to  be  a  consequence  rather  than  the  cause  of  the  abnormal  
T-­cell  activation  in  SLE.  Although  naïve  and  memory  T  cells  are  known  to  upregulate  
CTLA-­4   upon   activation   in   vitro   with   similar   kinetics,   the   latter   maintain   elevated  
expression  for  longer  time  periods  in  vitro  [30].  Therefore,  alterations  in  the  balance  of  
naı¨ve  and  memory  T  cells  may  provide  an  explanation   for   the  changes   in  CTLA-­4  
expression  we  have  observed.  However,  it  is  unclear  whether  there  is  an  increased  
ratio  of  memory  to  naïve  T  cells   in   lupus  [14,  43,  44].  Intriguingly,  although  lupus  T  
cells  proliferated  in  response  to  CD3/CD28  co-­stimulation  in  vitro,  they  were  unable  to  
upregulate  CTLA-­4  under   the  same  conditions.  This   increased  proliferation  without  
associated   increase   in   CTLA-­4   expression   may   be   partly   responsible   for   the  
dysregulation  characteristic  of  lupus  T  cells.  
The  increased  expression  of  CLTA-­4  ex  vivo  was  irrespective  of  lupus  disease  activity  
perhaps   suggesting   an   intrinsic,   possibly   genetic   defect   in   CLTA-­4   regulation.  
Importantly   elevation   in   CLTA-­4   is   not   a   universal   feature   of   peripheral   T   cells   in  
patients  with  autoimmune  rheumatic  diseases  since  T  cells  from  RA  and  PsA  showed  
normal  expression  levels.  Additional  support  for  a  role  for  CTLA-­4  in  the  pathogenesis  
of  lupus  comes  from  genetic  studies  linking  CTLA-­4  with  SLE  [20–27].  One  of  these  
polymorphisms  impairs  the  upregulation  of  CLTA-­4  upon  T-­cell  activation  [45].  CTLA-­
4   polymorphisms   have   been   associated   with   a   number   of   different   autoimmune  
diseases,  though  the  precise  contribution  of  CTLA-­4  to  their  pathogenesis  may  differ  
between  diseases.  Our  observation  that  CTLA-­4  was  increased  irrespective  of  disease  
activity  would  be  consistent  with  a  causal  link  rather  than  being  as  a  consequence  of  
disease.  
The  bulk  of  CTLA-­4  is  maintained  in  intracellular  stores  and  its  surface  expression  is  
tightly  regulated  by  a  process  of  exocytosis  and  continuous  endocytosis  [34].  As  well  
as   an   elevation   in   CTLA-­4   expression   in   lupus   T   cells,   we   noted   that   CLTA-­4  
internalisation  was  also  increased  ex  vivo,  which  would  tend  to  limit  its  expression.  
However,  whilst  the  rate  of  CTLA-­4  recycling  increased  following  in  vitro  activation  of  
healthy  T-­cells  as  noted  by  others  [46],  the  dynamics  of  CTLA-­4  internalisation  was  
unchanged   upon   activation   of   lupus   T   cells   in   vitro.   CTLA-­4   expression   can   be  
modified  by  increased  transport  to  the  cell  surface.  For  instance,  the  T-­cell  receptor  
interacting  molecule   associates   with   CTLA-­4   and   promotes   its   delivery   to   the   cell  
surface  [47].  This  results  in  increased  CTLA-­4  expression  despite  an  increased  rate  
of  CTLA-­4  internalisation.  Therefore,  if  CTLA-­4  is  delivered  to  the  cell  surface  at  an  
accelerated   rate   in   lupus   T   cells,   its   expression   may   remain   elevated   despite   an  
increased   rate   of   CTLA-­4   internalisation.   Surface   expression   of   CTLA-­4   is   also  
governed  by  a  motif  within  the  cytoplasmic  tail  which  when  phosphorylated  prevents  
its  association  with  clathrin-­associated  AP-­2  and  hinders  internalisation  [48].  It  is  well  
established  that  proximal  intracellular  signalling  is  dysfunctional  in  lupus  T  cells  and  
this  may  contribute  to  alterations  in  the  kinetics  of  CTLA-­4  recycling  [49].  In  addition,  
mutations  in  the  amino  acid  sequence  of  the  cytoplasmic  tail  of  CTLA-­4  can  lead  to  its  
accumulation  at  the  cell  surface  [50]  although  genetic  studies  have  not  indicated  that  
mutations  at  this  site  predisposes  to  SLE.  A  soluble  form  of  CLTA-­4  has  also  been  
described,  which  is  predominantly  expressed  on  resting  T-­cells  [51]  and  is  increased  
in   the   serum  of   patients  with  SLE   [52,   53].   The   soluble   form   of  CLTA-­4   lacks   the  
transmembrane  domain  of  the  CTLA-­4  gene  implying  that  alterations  in  its  expression  
are  not  secondary  to  changes  in  the  recycling  of  membrane  CTLA-­4.  CTLA-­4  is  an  
important  marker  of  Treg,  but  the  increase  in  CTLA-­4  expression  in  lupus  T  cells  was  
confined  to  the  FOXP3  population.  Although  we  found  a  substantial   increase  in  the  
number  of  CD4+FOXP3+  T  cells  from  lupus  patients  in  agreement  with  some  recent  
reports  [33],  this  could  be  a  further  indicator  of  abnormal  T-­cell  activation.  Indeed  a  
number   of   groups   have   noted   a   reduction   of   CD4+CD25hi   Treg   in   SLE   [54,   55].  
FOXP3  expression  is  known  to  be  increased  upon  activation  of  human  T  cells  [56–
58].  However,  the  increased  numbers  of  CD4+FOXP3+  T  cells  found  in  autoimmune  
inflammatory  environments  such  as  EAE  or   the   rheumatoid   joint   [59–61]  has  been  
used  to  support  the  argument  that  Treg  are  expanded  in  inflammation  but  are  unable  
to   establish   control   [62].   Although   defective   CTLA-­4   function   and   an   expanded  
CD4+FOXP3+  population  in  lupus  patients  may  not  be  connected,  there  is  a  striking  
parallel   found   in  CTLA-­4-­deficient  mice  [1,  2].   It  was  originally  noted  that   there   is  a  
marked  increase  in  the  number  of  CD41CD251  T  cells  in  mice  lacking  CTLA-­4.  The  
most   intuitive   explanation   is   that   this   simply   reflects   widespread   T-­cell   activation.  
However,   these   CD4+CD25+   T   cells   all   stain   brightly   for   FOXP3   suggesting   an  
expansion   of   Treg,   which   attempt   unsuccessfully   to   control   the   ensuing  
lymphoproliferation  and  autoimmunity  [63].  Recently,  using  antibody  blockade,  CTLA-­
4  has  been   shown   to   regulate  Treg  numbers  and  homeostasis   in   intact  mice   [12].  
Notwithstanding  these  observations,  the  precise  significance  of  increased  FOXP3+  T  
cells   in   lupus  patients   remains  unclear.  Defining   the  relationship  between  defective  
CTLA-­4  function  and  the  expanded  CD4+  FOXP3+  population  in  lupus  patients  could  
be  key  in  re-­establishing  tolerance  in  this  disease.  
The  exact  mechanisms  by  which  CTLA-­4  is  able  to  inhibit  T-­cell  activation  have  been  
studied  extensively;;  cross-­linking  CTLA-­4  in  the  context  of  CD3/CD28  stimulation  has  
been   shown   to   inhibit   T-­cell   proliferation   via   interaction   with   proximal   intracellular  
signalling  molecules  such  as  TCR-­z   [7,  64,  65].  We  show  here  that  CTLA-­4  fails  to  
regulate   proximal   T-­cell   signalling   and   T-­cell   proliferation   in   lupus   patients.   This  
paradoxical  association  between  increased  CTLA-­4  expression  and  loss  of  function  
has  not  been  reported  before  in  the  context  of  autoimmune  disease  or  inflammation.  
One  mechanism  to  explain  the  molecular  basis  of  CTLA-­4  inhibitory  action  includes  
the  location  of  CTLA-­4  within  membrane  lipid  microdomains  or  lipid  rafts.  In  healthy  
activated  T-­cells,  co-­ligation  of  CTLA-­4  during  TCR  stimulation  strongly   inhibits   the  
upregulation   of   membrane   lipid   microdomains   enriched   with   proximal   signalling  
molecules  [6].  We  show  here  that  in  lupus  T  cells  CTLA-­4  is  excluded  from  GM1+  lipid  
microdomains  and  its   ligation  does  not   inhibit  GM1  expression  following  CD3/CD28  
costimulation.  During  T-­cell  activation  a  pool  of  cell  surface  CTLA-­4  is  concentrated  in  
lipid  microdomains  and  associates  with  the  TCR-­z  chain  [7,  8].  Thus  the  exclusion  of  
CTLA-­4   from  membrane  microdomains  may   account   for   the   inability   of  CTLA-­4   to  
inhibit  phosphorylation  of  proximal  signalling  molecules  and  T-­cell  proliferation   in  T  
cells  from  patients  with  SLE  compared  with  healthy  controls.  
In  summary,  our  findings  demonstrate  abnormalities  in  T-­cell  CTLA-­4  biology  in  lupus  
patients,  and  provide  new  insight  into  the  function  of  CTLA-­4  in  a  disease  setting.  It  is  
possible   that   targeting   CTLA-­4   on   responder   T   cells,   or   altering   the   membrane  
microdomains  that  exclude  CTLA-­4,  could  restore  T-­cell  function  in  patients  with  SLE.  
  
Materials  and  Methods  
Patients  and  controls  
Peripheral  blood  was  obtained  from  healthy  donors  and  patients  with  SLE,  RA  and  
PsA   attending   the   Rheumatology   clinic   at   University   College   Hospital,   London.  
Patients   fulfilling   the   revised   classification   criteria   of   the   American   College   of  
Rheumatology  for   lupus  were  included  in  this  study.  Disease  activity  was  assessed  
using  British  Isles  Lupus  Assessment  Group  Score.  All  patients  studied  were  receiving  
less   than   10mg   prednisolone   and   no   immunosuppression   other   than  
hydroxychloroquine  for  at  least  1  month  before  analysis.  Inactive  patients  were  either  
untreated  or  received  only  hydroxychloroquine.  Age  and  sex-­matched  healthy  donors  
were  used  as  controls.  All  RA  patients  had  a  disease  activity  score  (DAS28)  of  >5.1.  
PsA  patients   had  at   least   three   swollen  and   tenderjoints.  CD4+   lymphocytes  were  
purified   from   PBMC   by   negative   selection   (Miltenyi   Biotech).   T   responders  
(CD4+CD25-­CD127+)  were   isolated   using   a   cell   sorter   (FACS-­Aria,  BD).  Approval  
was  given  by  the  Ethics  Committee  of  the  University  College  Hospital  London,  patients  
and  control  donors  gave  their  informed  consent.  
 
  
Antibodies  and  reagents  
Antibodies  for  flow  cytometry  and  confocal  microscopy:  FITC-­CTLA-­4  (48815)  from  R  
&  D  Systems;;  PECy7-­CD25   (BC96),  PECy5-­CD127   (eBioDR5),  and  Alexa-­Fluor®-­
488-­FOXP3  (PCH101)  from  eBioscience;;  APC-­,  PE-­  or  FITC-­CD4  (RPA-­T4),  Biotin-­  
or   PE-­CTLA-­4   (BNI3.1),   Biotin-­CD28,   PE-­Ki67,   PECy7-­and   APC-­streptavidin   and  
fluorochrome-­conjugated  isotype  controls  from  BD  Bioscience.  Alexa  Fluor®-­594-­CTB  
and   goat   anti-­rabbit   Alexa   Fluors-­647   from   Invitrogen,   FITC-­CTB   from  Sigma.   For  
biological  assays,  purified  antibodies  to  CD3  (HIT3a),  CD28  (CD28.2),  CTLA-­4    (BNI3)  
from   BD   Bioscience.   Antibody-­coated   stimulating   beads   Dynabeadss   M-­280  
Tosylactivated   (Dynal   Biotech)   were   coated   with   anti-­CD3,   anti-­CD28   (10mg/mL,  
each)   and   anti-­CTLA-­4   (50   mg/mL)   antibodies   (or   isotype   control)   following  
manufacturer’s   instructions.   The   following   antibody   was   used   for   protein  
phosphorylation  analysis  by  flow  cytometry:  Alexa-­Fluors-­488-­phospho-­Y142  CD3-­z  




Membrane  staining  for  phenotyping  was  carried  out  with  the  relevant  antibodies  using  
1%  FBS-­PBS  for  30  min  at  room  temperature.  Intracellular  staining  was  carried  out  
after  fixation/permeabilisation  (eBioscience).  Cell  phenotyping  was  read  using  a  BD-­




FACS-­sorted  Treg  were  rested  for  1  h  at  371C,  and  then  stimulated  for  1  h  at  37ºC  
with  PMA   (10  ng/mL).  After   two  washes,   cells  were  membrane-­stained  with  FITC-­
CTLA-­4  for  1  h   in   ice.  Following  staining,  cells  were   incubated  at  37ºC  for  different  
time   periods   and   then   fixed   and   mounted   for   confocal   microscopy   analysis.  
Alternatively,  following  staining  for  CTLA-­4  and  incubation  at  37ºC,  cells  were  acid-­
washed  with  PBS  (pH  2.0)  in  order  to  remove  non-­internalised  Ab-­labelled  CTLA-­4.  
Cells  were  fixed  with  2%  PFA  and  analysed  by  flow  cytometry.  CTLA-­4  internalisation  
rate  was  calculated  as  the  ratio  of  MFI  acid  wash/MFI  PBS  wash  x100.  
  
Cell  activation  
For  cell  signalling  analyses,  FACS-­sorted  responder  T  cell  were  rested  for  1  h  in  RPMI  
with   0.5%   human   serum.   Cells   were   incubated   with   anti-­CD3/CD28   antibodies   (1  
mg/106  cells,  each)  on  ice  for  20  min,  washed  with  ice-­cold  PBS  and  anti-­CD3/CD28  
antibodies   cross-­linked   by   goat   anti-­mouse   IgG   F(ab’)2   (2  mg/106cells)   on   ice   for  
20min.  After  washing,  cells  were  resuspended  in  warm-­PBS  and  incubated  for  10min  
at  37ºC.  Cells  were  fixed/  permeabilised  with  2x  Fix/Perm  buffer  (eBioscience)  and  
stained  with  the  appropriate  antibody.  Analysis  of  GM1  expression  was  measured  in  
T-­responder  cells  following  72  h  stimulation  beads  coated  with  anti-­CD3/CD287anti-­
CTLA-­4  or   isotype   control   and   staining  with  CTB-­FITC.  For   proliferation   assays,   T  
responders  were   incubated   in   the  presence  of  anti-­CD3/CD287anti-­CTLA-­4  F(ab’)2  
for  3  days  and  then  pulsed  with  [3H]thymidine,  incubated  for  16  h  before  harvesting,  




Images  were  taken  with  a  63x  objective  in  a  Leica  DMIRE2  microscope.  Analysis  of  
co-­localisation   in   composite   merged   RGB   images   was   carried   out   with   ImageJ  




All  values  are  expressed  as  means±SEM.  Analysis  of  significance  was  by  the  unpaired  
or  paired  two-­tailed  Student’s  t-­test  with  Welch’s  correction  for  two  groups.  
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Figure  1.   Increased  expression  of  surface  and   intracellular  CTLA-­4   in  T  cells   from  
patients  with  SLE.  Representative  FACS  plots  and  cumulative  data   for  percentage  
CD4+  T  cells  expressing  (A)  total  (t)  and  (B)  surface  (s)  CTLA-­4.  (C)  Cumulative  data  
of   total   CTLA-­4   expression   in   CD4+   T-­cells   from   healthy   donors   compared   with  
patients   with   active   and   inactive   lupus   disease   and   patients   with   RA   and   PsA   as  
disease  controls.  Active  lupus  defined  by  global  British  Isles  Lupus  Assessment  Group  
scores  of46.  Data  from  37  healthy  donors  and  40  patients  with  SLE.  In  (C),  data  from  
active   eight   patients   with   RA   and   eight   patients   with   active   PsA   are   included.  
Mean±SEM,  *p=0.01,  **p=0.008,  ***p=0.0002.  
  
Figure  2.  Increased  CTLA-­4  is  independent  of  FOXP3  expression  but  associated  with  
increased   T-­cell   activation   in   lupus   patients.   (A)   Representative   FACS   plots   and  
cumulative  data  of  tCTLA-­4  expression  in  CD4+FOXP3-­  and  CD4+FOXP3+  T  cells,  
**p=0.008.  (B)  CD28  and  tCTLA-­4  expression  in  CD41T  cells,  cumulative  data  shows  
CD28  MFI  and  %  CD28+  in  the  CTLA-­4+  population  p=0.0001,  (C)  FOXP3  and  Ki67  
expression   in   CD4+   T   cells,   cumulative   data   shows   Ki67   expression   in   the   CD4+  
FOXP3-­  subset  **p=0.006.  (D)  PBMC  from  33  healthy  controls  and  35  patients  with  
SLE  were  stained  for  CD4  and  FOXP3.  The  cumulative  data  indicates  the  percentage  
of  CD4+FOXP3+  T  cells,  ***p=0.0001.  (E)  Representative  histograms  and  cumulative  
data   of   tCTLA-­4   expression   in   the  CD41FOXP3   subset   defined   according   to   Ki67  
expression,   *p=0.01.   Results   from   ten   healthy   donors   and   ten   patients   with   SLE,  
mean±SEM.  
  
Figure  3.  Abnormal  kinetics  of  CTLA-­4  expression  in  lupus  T  cells  following  in  vitro  
activation.  T   responder  cells   (CD4+CD25-­CD127+)  were   isolated  by  FACS-­sorting.  
(A)  Cells  were  cultured  in  medium  alone  or  with  soluble  antibodies  to  anti-­CD3/CD28  
for  24  h  before   staining   for   tCTLA-­4.  Cumulative   results   from   five  healthy  and   five  
patients  with  SLE,  *p=0.01.  (B)  T-­responder  cells  (CD4+CD25-­CD127+)  were  treated  
with  PMA  to   induce  CTLA-­4  accumulation  at   the  cell  membrane.  PMA-­treated  cells  
were   membrane-­stained   for   CTLA-­4   and   then   incubated   to   allow   CTLA-­4  
internalisation.  CTLA-­4   internalisation  was  analysed  by  confocal  microscopy   (B)  or  
flow  cytometry  (C).  Microscopy  analysis  in  (B)  showed  areas  of  CTLA-­4  aggregation  
after  2  min  in  healthy  T-­cells  (arrow)  compared  with  a  diffuse  staining  pattern  seen  in  
SLE  T  cells  (arrow).  Results  are  representative  of  six  healthy  controls  and  six  patients  




Figure   4.   Defective   inhibition   of   lupus   T-­cell   activation   and   proximal   signalling   by  
CTLA-­4.  (A)  Purified  healthy  and  lupus  T  responder  cells  (CD4+CD25-­CD127+)  were  
activated  with  anti-­CD3/CD287anti-­CTLA-­4.  Data   from  a   representative  experiment  
with  unstimulated  T  cells  shown  as  a  control  and  (**p=0.005).  (B)  Cumulative  data  of  
the   proliferation   in   cells   stimulated   with   anti-­CD3/CD28   compared   with   anti-­
CD3/CD28/CTLA-­4   stimulated   cells   expressed   as   a   percentage.   Results   from   ten  
healthy  donors  and  six  patients  with  SLE,  ***p=0.003.  (C)  FACS-­sorted  T-­responder  
cells  (CD4+CD25-­CD127+)  were  stimulated  with  anti-­CD3,  anti  CD28±  anti-­CTLA-­4  
antibodies   (Materials   and   methods).   Phosphorylation   of   signalling   molecules   was  
evaluated   by   flow   cytometry   after   intracellular   staining   with   phospho-­specific  
antibodies.  (D)  Cumulative  data  of  the  percentage  change  in  levels  of  TCR-­z tyrosine-­
phosphorylation   in   stimulated   compared   with   non-­stimulated   purified   responder   T  
cells.  Results  are  from  five  healthy  controls  and  five  lupus  patients,  *p=0.04.  
  
  
Figure   5.   Altered   membrane   localisation   of   CTLA-­4   in   lupus   T   cells.   (A)  
Representative   histograms   and   cumulative   data   showing   lipid   raft   (CTB/GM1)  
expression  in  purified  T-­responder  cells  after  culture  with  anti-­CD3/CD287anti-­CTLA-­
4   antibodies   or   isotype   control   (72   h).   Data   from   six   healthy   controls   and   seven    
patients  with  active  SLE.  **p=0.005.  (B)  Purified  responder  T  cells  were  labelled  with  
CTB  (red)  followed  by  crosslinking  with  anti-­CTB  antibodies  in  order  to  patch  the  areas  
of  lipid  rafts  in  the  membrane.  Cells  were  fixed  and  stained  for  intracellular  CTLA-­4  
(blue)  and  analysed  by  confocal  microscopy.  Colocalisation  of  CTLA-­4  and  CTB   is  
indicated  by  pink  colour.  (C)  Analysis  of  co-­localisation  of  membrane  microdomains  
and  CTLA-­4.  Representative  dot  plots  indicate  the  distribution  of  red  (CTB)  and  blue  
(CTLA-­4)   pixels.  Cumulative   data   showing   the   percentage   of   cells   showing  CTLA-­
4/CTB   co-­localisation.   Representative   images   of   at   least   25   cells   from   6   healthy  
controls  and  6  patients  with  SLE.  Bar=5  µM,  ***p=0.0006.  
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